OBJECTIVE: To estimate the risk of malignant diseases in families of probands with the same mutation in the BRCA2 gene. DESIGN: A cohort study using record linkage of a breast cancer family resource and the Icelandic Cancer Registry. SETTING: Iceland. SUBJECTS: Families of 995 breast cancer patients, from which 887 were tested for a single founder 999del5 mutation; 90 had the mutation and 797 did not. RESULTS: Relatives of probands with the mutation had significantly increased relative risk (RR) of breast cancer. For first degree relatives, the RR was 7.55 (95% CI 6.04 to 9.03) but was 1.72 (95% CI 1.49 to 1.96) in first degree relatives of probands without the mutation. For prostate and ovarian cancer, the first and second degree relatives of probands with the mutation had a significantly increased RR, but in families of probands without the mutation no significant familial risk was found. CONCLUSIONS: The 999del5 mutation in the BRCA2 gene explains a substantial proportion of familial risk of breast cancer in Iceland, but significant familial risk remains in relatives of probands without the mutation. For prostate and ovarian cancer, the mutation accounts for most of the familiality observed in families of breast cancer patients.
OBJECTIVE: To estimate the risk of malignant diseases in families of probands with the same mutation in the BRCA2 gene. DESIGN: A cohort study using record linkage of a breast cancer family resource and the Icelandic Cancer Registry. SETTING: Iceland. SUBJECTS: Families of 995 breast cancerpatients, from which 887 were tested for a single founder 999del5 mutation; 90 had the mutation and 797 did not. RESULTS: Relatives of probands with the mutation had significantly increased relative risk (RR) of breast cancer. For first degree relatives, the RR was 7.55 (95% CI 6.04 to 9.03) but was 1.72 (95% CI 1.49 to 1.96) in first degree relatives of probands without the mutation. For prostate and ovarian cancer, the first and second degree relatives of probands with the mutation had a significantly increased RR, but in families of probands without the mutation no significant familial risk was found. CONCLUSIONS: The 999del5 mutation in the BRCA2 gene explains a substantial proportion of familial risk of breast cancer in Iceland, but significant familial risk remains in relatives of probands without the mutation. For prostate and ovarian cancer, the mutation accounts for most of the familiality observed in families of breast cancerpatients.
Authors: R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem Journal: Nature Date: 1995 Dec 21-28 Impact factor: 49.962
Authors: Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding Journal: Science Date: 1994-10-07 Impact factor: 47.728
Authors: J Gudmundsson; G Johannesdottir; A Arason; J T Bergthorsson; S Ingvarsson; V Egilsson; R B Barkardottir Journal: Am J Hum Genet Date: 1996-04 Impact factor: 11.025
Authors: S V Tavtigian; J Simard; J Rommens; F Couch; D Shattuck-Eidens; S Neuhausen; S Merajver; S Thorlacius; K Offit; D Stoppa-Lyonnet; C Belanger; R Bell; S Berry; R Bogden; Q Chen; T Davis; M Dumont; C Frye; T Hattier; S Jammulapati; T Janecki; P Jiang; R Kehrer; J F Leblanc; J T Mitchell; J McArthur-Morrison; K Nguyen; Y Peng; C Samson; M Schroeder; S C Snyder; L Steele; M Stringfellow; C Stroup; B Swedlund; J Swense; D Teng; A Thomas; T Tran; M Tranchant; J Weaver-Feldhaus; A K Wong; H Shizuya; J E Eyfjord; L Cannon-Albright; M Tranchant; F Labrie; M H Skolnick; B Weber; A Kamb; D E Goldgar Journal: Nat Genet Date: 1996-03 Impact factor: 38.330
Authors: S Thorlacius; L Tryggvadottir; G H Olafsdottir; J G Jonasson; H M Ogmundsdottir; H Tulinius; J E Eyfjord Journal: Lancet Date: 1995-08-26 Impact factor: 79.321
Authors: Gabriela Torres-Mejía; Robert Royer; Marcia Llacuachaqui; Mohammad R Akbari; Anna R Giuliano; Louis Martínez-Matsushita; Angélica Angeles-Llerenas; Carolina Ortega-Olvera; Elad Ziv; Eduardo Lazcano-Ponce; Catherine M Phelan; Steven A Narod Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-04 Impact factor: 4.254
Authors: Ilir Agalliu; Erika M Kwon; Claudia A Salinas; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford Journal: Cancer Causes Control Date: 2009-11-10 Impact factor: 2.506
Authors: Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin Journal: Mol Oncol Date: 2009-02-21 Impact factor: 6.603
Authors: Tryggvi Thorgeirsson; Kristina M Jordahl; Richard Flavin; Mara Meyer Epstein; Michelangelo Fiorentino; Swen-Olof Andersson; Ove Andren; Jennifer R Rider; Juan Miguel Mosquera; Helen Ingoldsby; Katja Fall; Laufey Tryggvadottir; Lorelei A Mucci Journal: Carcinogenesis Date: 2016-01-16 Impact factor: 4.944